

January 23, 2026

BSE Limited,
(Corporate Relationship Department),
P J Towers,
Dalal Street, Fort,
Mumbai- 400 001

BSE Code: 530343

National Stock Exchange of India Ltd., (Listing &
Corporate Communications),
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051.

NSE Symbol: GENUSPOWER

Dear Sir,

Sub: Newspapers advertisement for notice of Record Date

Ref: Scheme of Arrangement, which inter-alia included the demerger of the Strategic Investment Business (the “Demerged Undertaking”) of Genus Power Infrastructures Limited (the “Company”) into Genus Prime Infra Limited (the “Resulting Company”), along with their respective shareholders and creditors (the “Scheme”) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013

Please find enclosed a copy of the newspaper advertisement published in the newspapers, viz. *Business Standard* (English – all editions) and *Business Standard* (Hindi), for notice of record date for the purpose of determining the entitlement of shareholders under the Scheme of Arrangement.

Kindly take the same on record.

Thanking you,

For **Genus Power Infrastructures Limited**

Puran Singh Rathore
(Joint Company Secretary & Compliance Officer)
Encl. as above

Non-US uptick seen driving gains for Dr Reddy's Labs

Brokerages bullish on company despite Q3FY26 margin pressure

SIRALI GUPTA
Mumbai, 22 January

Shares of Dr Reddy's Laboratories jumped 5.3 per cent on Thursday to ₹1,217 apiece, making it the top gainer in the Nifty 50 and the BSE 100 indices. By comparison, the Nifty 50 was up 0.53 per cent at 25,289. The buying on the counter came after the company reported its results for the third quarter (October–December) of 2025–26 (Q3FY26) on Wednesday, after market hours. Analysts are broadly constructive on Dr Reddy's Labs' medium-term prospects despite Q3FY26 margin pressure, with views split on near-term risks.


In Q3FY26, Dr Reddy's Labs reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago. The firm's revenue from operations rose to ₹8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from ₹8,357 crore in Q3FY25. The company's earnings before interest, taxes, depreciation, and amortisation (EBitda) stood at ₹2,049 crore, compared to ₹2,298 crore a year ago.

Motilal Oswal Research said Dr Reddy's Labs delivered a better than expected Q3FY26, with strong execution in India, Europe and Russia, and favourable currency movement more than offsetting the drag due to weaker contribution from the generic version of cancer drug Revlimid, resulting in an earnings beat.

The brokerage cut its FY26 estimates by 4 per cent to factor in a delay in the launch of diabetes/weight control drug semaglutide in Canada, but raised FY27 estimates by 6 per cent on better growth prospects across India, Europe and Russia. It has a "neutral" rating, with a target price of ₹1,220. JM Financial believes margin pressure reflects ongoing headwinds in the US market. However, it sees strong growth excluding the US market, a



Health concerns



rich filing pipeline, and upcoming semaglutide launches providing medium-term earnings visibility, with the worst largely factored into current valuations. In Q3FY26, the company's operating profit margins contracted sharply by 579 basis points (bps) Y-o-Y, reflecting lower Revlimid sales, an adverse product mix, and sustained pricing pressure, although overall profitability still beat Street expectations. It has raised its target price to ₹1,545 from ₹1,522.

Elara Capital estimates one-off Revlimid sales of ₹50–60 million in Q3FY26, and believes that the opportunity window has closed.

North America's business was down Y-o-Y and quarter-on-quarter (Q-o-Q), as expected. All the other businesses performed in line or posted a beat. India's business grew 19 per cent Y-o-Y, and the company expects it to sustain above 15 per cent, which is a major positive highlight. The brokerage maintained its FY26–FY28 core earnings estimates broadly. It has a "buy" rating target price of ₹1,588.

Emkay Research said Dr Reddy's Q3FY26 margin performance was in line with its expectations, and about 100 bps ahead of Street estimates on an adjusted basis (excluding one-offs). The brokerage noted that a higher adjusted gross margin was offset by higher selling, general, and administrative spending. While the brokerage sees limited room for further negative pipeline surprises, its base case is that FY28 earnings per share (EPS) will still be lower than FY25 earnings. It marginally raised earnings estimates after tweaking domestic growth and forex assumptions, and rolling forward to December 2027 earnings. The brokerage has a "reduce" rating, though it has raised its target price from ₹1,000 to ₹1,200.

The brokerage cut its FY26 estimates by 4 per cent to factor in a delay in the launch of diabetes/weight control drug semaglutide in Canada, but raised FY27 estimates by 6 per cent on better growth prospects across India, Europe and Russia. It has a "neutral" rating, with a target price of ₹1,220. JM Financial believes margin pressure reflects ongoing headwinds in the US market. However, it sees strong growth excluding the US market, a



MANY FUNDS WITH SIMILAR HOLDINGS?

Exit some and move fresh money into other segments

KARTHIK JEROME

The Securities and Exchange Board of India (Sebi) plans to tighten scrutiny when a fund house launches a new sector or thematic scheme. It will seek a model portfolio and examine whether the proposed fund overlaps with an existing scheme from the same fund house by more than 50 per cent. While this addresses overlaps at the fund-house level, investors must also scrutinise their own portfolios for overlaps.

Overlap refers to the same stocks appearing across fund portfolios. "Such overlapping funds move in tandem, reducing diversification benefit," says Kaustubh Belapurkar, director–manager research, Morningstar Investment Research India.

Mindless addition of funds
Overlap typically arises when investors add too many funds indiscriminately, often belonging to the same category, based on

past returns. Buying multiple schemes run by the same fund manager (say, a flexicap and an ELSS fund) also results in overlap. Investing in more than one sector or thematic fund from the same sector or theme, which have a limited universe of stocks to choose from, increases overlap. Many of the stocks held by sector and thematic funds are already present in diversified funds.

New fund offers also contribute. As portfolios are not disclosed at launch, investors are unable to assess common holdings," says Vishal Dhawan, founder and chief executive officer, Plan Ahead Wealth Advisors.

How to check for portfolio overlap
For a basic check, download the portfolios of the two funds in Excel and identify the common stocks — at least the top 10. "Examine not just the names but also the weightages. A stock having 10 per cent weight in one fund and 1 per cent in another

would cause only a minor overlap," says Dhawan.


Several mutual fund websites have online tools for checking portfolio overlaps, though some require a subscription. To prevent overlap at the portfolio construction stage, diversify by market cap, style, and geography.

Diversification by market cap

Different market caps perform differently across cycles. "Large caps offer stability when markets struggle. Mid and smallcap stocks generate higher long-term returns but experience sharper drawdowns," says Deepesh Raghaw, a Sebi-registered investment advisor. He adds that diversifying across large, mid and small cap funds can combine the benefits of participation in rallies with downside protection. Investors with higher risk tolerance and longer investment horizons can have higher exposure to mid and smallcap funds.

Diversification by style
Investment styles — growth, value, momentum and quality —

US market: Return booster



also go through cycles. "No one can predict which style will outperform at which point in time," says Belapurkar. Blending various styles in a portfolio can ensure that some part of it performs, irrespective of which style is in favour. Investors can assess a fund's style through fund disclosures, style boxes, Sebi's categorisation, and fund managers' commentary on their investment approach.

Diversification by geography

Geographical diversification smoothens portfolio performance as different markets don't always move sync. "Domestic and international markets respond to varied drivers such as commodity cycles, technology cycles, interest rates, inflation and geopolitics," says Dhawan. Belapurkar adds that overseas exposure provides access to businesses not available on the local bourses. Raghaw points out that international diversification offers a hedge against rupee depreciation.

How to remove overlap

Some overlap is inevitable. "If it is excessive, investors may need to exit certain schemes, while minimising tax incidence and exit load. Alternatively, directing fresh money into underrepresented areas can gradually reduce overlap," says Dhawan.

To restructure your portfolio, begin by deciding on an asset allocation across equity, debt, precious metals and real estate based on risk tolerance and horizon. Next, decide the exposure to sub-asset classes. Finally, Raghaw cautions that before adding a new fund to the portfolio, investors must ensure it will add value.

Unpaid highway toll could crash your plan to sell a vehicle: Here is how

The government has announced rules that bar people from transferring ownership of vehicles, moving them across states, or renewing fitness certificates if they have not paid highway toll.

If a vehicle has any unpaid national highway toll dues:

- A no objection certificate (NOC) for ownership transfer will not be issued
- An NOC for inter-state vehicle

The most significant impact for

Read full report here: mybs.in/2g39n3f

vehicle owners is the direct link between toll clearance and routine vehicle documentation.

What this means for vehicle owners

For individual motorists, the new rules mean toll payments are no

longer limited to highway use alone. Unpaid dues can now surface later when selling vehicle, renewing documents, or relocating.

For the government and the National Highways Authority of India, the move supports the roll-out of Multi-Lane Free Flow tolling, which will enable barrier-less toll collection across highways.

COMPILED BY AMIT KUMAR

EICHER

EICHER MOTORS LIMITED

CIN: L34102DL1982PLC129877

Regd. Office: Office number 1111, 11th Floor, Ashoka Estate, Plot Number 24, Barakhamba Road, New Delhi - 110001

Telephone: +91 11 41095173

Email: investors@eichermotors.com, Website: www.eichermotors.com

Notice for Loss of Share Certificates

Notice is hereby given that the following Share Certificate(s) of Eicher Motors Limited ("the Company") have been reported as lost/misplaced/stolen by the below mentioned registered holder(s) and they have applied to the Company for issue of duplicate share certificate(s).

Name of Shareholder	Folio No.	Certificate No.	Distinctive Nos.	No. of shares
		From	To	(Face value Rs. 10 each)
Anantrai Lavechand Mehta	54170	37388	3736901	100
		92423	18941970	100
Nargis Raj Kumar jointly with Sonu RajKumar	31015	41910	4189101	100
Sapna Kumar	53514	90961	18839700	50
Meera K Varghese	48282	18517	1849801	1849900
		81679	18125839	100

Any person who has a claim in respect of the said certificate(s) should lodge his/her claim with all supporting documents with the Company at its registered office address at Office No. 1111, 11th Floor, Ashoka Estate, Plot No. 24, Barakhamba Road, New Delhi-110001, India. If no valid and legitimate claim is received within 15 days from the date of publication of this notice, the Company will proceed to issue duplicate share certificate(s) of Letter of Confirmation to the person(s) named above subject to verification of all documents and no further claim would be entertained from any other person(s).

For Eicher Motors Limited
Sd/-
Atul Sharma
Place: New Delhi
Date: January 22, 2026
Company Secretary & Compliance Officer

ANGEL ONE LIMITED

Regd. Off: 601, 6th Floor, Akruti Star, Central Road, MIDC, Andheri East, Mumbai - 400093 SEBI Registration No (Stock Broker): INZ000161534

PUBLIC NOTICE

This is to inform you that a person operating through mobile number "9162278130", "9315342663", "7976417086", "7909563464", "8505974797" & Navin Aranya - "Demer" has been fraudulently using our Company name Angel One Ltd. to carry out scams and illicit activities by representing themselves as our officials/representatives.

Be Cautious with Unknown Callers Claiming to Represent Angel One -
Scammers often impersonate to gain access to your personal or financial information.

This is to inform that, "ALODMA/ALODMAPRO" applications on play store/IOS are wrongfully and deceptively using the brand name and logo of Angel One Limited to deceive the general public in believing it to be associated with Angel One Limited. Further, certain whatsapp / telegram groups are wrongfully and deceptively using the brand name logo of Angel One Limited along with name & image of senior officials to collect money and offer fake investment returns and deceive the general public in believing it to be associated with Angel One Limited. Investors and General Public are hereby informed that Angel One Limited does not have any association and/or relation, directly or indirectly with "ALODMA/ALODMAPRO" applications or private whatsapp / telegram groups or above individuals in any capacity.

Angel One Limited will not be liable in any manner of financial loss and/or consequence of dealing with such applications or weblinks or individuals. Please note that any person dealing with them will be dealing at his/her own risk and responsibility.

Date : 23.01.2026

Genus Power Infrastructures Limited
(Registered Office: G-123, Sector-63, Noida-201307, Uttar Pradesh)
Corporate Office: SPL-3, RICOH Industrial Area, Sitapur, Tonk Road, Jaipur-302022, Rajasthan
(Tel.: +91-120-2581999; E-mail: genus@genus.in; Website: www.genuspower.com; CIN: L51999UP1992PLC059797)

NOTICE OF RECORD DATE

Scheme of Arrangement amongst Genus Power Infrastructures Limited ("Company") or "Demerged Company", Genus Prima Infra Limited ("Resulting Company"), Sansar Infrastructure Private Limited, Star Vanjhi Private Limited, Sunima Trading Private Limited, and Yajur Commodities Limited and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme")

With reference to the above Scheme and pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company has fixed the Record Date as **Friday, February 06, 2026**, for the purpose of determining the shareholders of the Company to whom fully paid up equity shares of the Resulting Company shall be issued in consideration for the demerger of the Investment Business Division of the Company into the Resulting Company.

In view of the above, the Equity shareholders of the company whose names are recorded in the Register of Members and Records of Depositories as a Member of the Company on **Friday, February 06, 2026**, being the Record Date fixed by the Board of Directors, will be entitled for allotment of 1 (One) Equity share of face value ₹2/- each of the Resulting Company as fully paid up for every 6 (Six) Equity shares of face value of ₹1/- (One) each of the Company.

After the allotment of the Equity shares by the Resulting Company, it would also complete necessary formalities and undertake steps to have the said Equity Shares listed on the stock exchange where its existing Equity Shares are listed.

In case any member holds equity shares in the Demerged Company in physical form, the Resulting Company will not issue its equity shares to such member but will, subject to Applicable Laws, issue the corresponding equity shares in dematerialized form into the Suspense Escrow account in the name of the Resulting Company where such equity shares will be held on behalf of such member. The equity shares of the Resulting Company, once such member provides details of his/ her/ its demat account to the Resulting Company, along with such documents as maybe required, by sending an email to cs.genusprime@gmail.com. The respective member shall have all the rights of the shareholders of Resulting Company, including the right to receive dividend, voting rights and other corporate benefits, pending the transfer/transmission of equity shares from the suspense escrow account.

Any fractional entitlement arising out of the issue and allotment of the shares issued by the Resulting Company, shall be rounded up to the next integer and be issued free from all liens, charges, equitable interests, encumbrances and other third-party rights of any nature whatsoever.

The equity shares to be issued by the Resulting Company, in respect of equity shares of the Demerged Company which are held in abeyance under the provisions of Section 126 of the Companies Act, 2013 (erstwhile Section 206A of the Companies Act, 1956) or are otherwise held, pending allotment or settlement of the dispute by order of a court or otherwise, also be kept in abeyance by the Resulting Company.

The information contained in this Notice is available on the website of the Company at <https://genuspower.com> and also on the website of the Stock Exchanges viz. BSE Limited at <https://www.bseindia.com> and the National Stock Exchange of India Limited at <https://www.nseindia.com>.

